Misplaced Pages

TP0586532

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
TP0586532
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 4-imidazol-1-yl]methyl]-1,2-oxazol-5-yl]phenyl]ethynyl]-3-azabicyclohexan-3-yl]butanoic acid
CAS Number
PubChem CID
ChemSpider
ChEMBL
PDB ligand
Chemical and physical data
FormulaC26H28N4O4
Molar mass460.534 g·mol
3D model (JSmol)
SMILES
  • C(C1=NC=CN1CC2=NOC(=C2)C3=CC=C(C=C3)C#CC454CN(C5)CCCC(=O)O)O
InChI
  • InChI=1S/C26H28N4O4/c1-17(31)26-27-10-12-30(26)14-20-13-24(34-28-20)19-7-4-18(5-8-19)6-9-21-22-15-29(16-23(21)22)11-2-3-25(32)33/h4-5,7-8,10,12-13,17,21-23,31H,2-3,11,14-16H2,1H3,(H,32,33)/t17-,21?,22-,23+/m0/s1
  • Key:PULUMLQUYYSBOR-BOSCWZPRSA-N

TP0586532 is an experimental antibiotic drug, which acts as a potent and selective inhibitor of the bacterial enzyme UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC). This enzyme is important for the production of Lipid A, a key component of the cell membrane of Gram-negative bacteria. Previous inhibitors of LpxC have failed to progress into clinical trials in humans, mostly because of off-target cardiovascular toxicity, so TP0586532 was based on a different structural class which is hoped to reduce this risk. In animal studies it shows activity against carbapenem-resistant Klebsiella pneumoniae but has not yet progressed into human trials.

See also

References

  1. Ushiyama F, Takashima H, Matsuda Y, Ogata Y, Sasamoto N, Kurimoto-Tsuruta R, et al. (January 2021). "Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532". Bioorganic & Medicinal Chemistry. 30: 115964. doi:10.1016/j.bmc.2020.115964. PMID 33385955.
  2. Fujita K, Takata I, Yoshida I, Honma Y, Okumura H, Otake K, et al. (May 2022). "Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model". Journal of Infection and Chemotherapy. 28 (5): 635–642. doi:10.1016/j.jiac.2022.01.004. PMID 35131156.
  3. Fujita K, Takata I, Yoshida I, Okumura H, Otake K, Takashima H, et al. (February 2022). "TP0586532, a non-hydroxamate LpxC inhibitor, has in vitro and in vivo antibacterial activities against Enterobacteriaceae". The Journal of Antibiotics. 75 (2): 98–107. doi:10.1038/s41429-021-00486-3. PMID 34837061.
Categories: